Ionis Shares Plunge on Trial Miss, Securities Investigation Looms

What happened

Ionis Pharmaceuticals shares dropped over 20% after the Phase-3 CARDIO-TTRansform trial for eplontersen in ATTR-CM missed its primary endpoint. Following the decline, law firm Levi & Korsinsky announced a pending investigation into potential securities law violations, adding legal overhang. Despite the setback, management reaffirmed full-year 2026 revenue guidance of $875-900 million and highlighted a $1.9 billion cash position. Key near-term catalysts remain: TRYNGOLZA's sHTG launch in July, zilganersen PDUFA on Sep 22, and bepirovirsen PDUFA on Oct 26. However, the investigation introduces uncertainty that could amplify selling pressure and delay investor re-engagement.

Implication

The fundamental thesis hinges on TRYNGOLZA's commercial ramp and successful PDUFA outcomes for zilganersen and bepirovirsen. While the trial miss was a known risk, the investigation adds an unmodeled legal overhang. Patience is warranted, but conviction requires clear evidence of product adoption and regulatory approvals.

Thesis delta

The CARDIO-TTRansform failure was already captured as a thesis risk in the DeepValue report, but the securities investigation introduces a new legal risk not previously considered. This may widen the discount to intrinsic value and delay sentiment recovery, though the core catalysts and balance sheet remain intact.